PP
Piramal Pharma Limited
PPLPHARMA.NS · NSE
₹214.22 -0.13% (-₹0.27)
1M +2.87%
Market Cap ₹283.9B
P/E Ratio -
Div. Yield -
ROE 3.86%
Piotroski F-Score Weak
2/9Valuation
27 /100
Expensive EV/EBITDA 26.26x
P/S 3.08x
P/B 3.48x
Growth
43 /100
Stable EPS growth 39.63%
Rev. growth 11.87%
Book val. growth 6.66%
Profitability
27 /100
Weak Gross margin 35.75%
Net margin 3.41%
Op. margin 1.66%
Quality
0 /100
Poor ROE 3.86%
ROIC N/A
ROA N/A
Debt
78 /100
Low Debt/Equity 0.00x
Int. coverage 0.65x
Net debt/EBITDA 0.00x
Stability
44 /100
Moderate Beta 0.32x
Rev. volatility 3.30%
EPS volatility 267.82%
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o PPLPHARMA.NS
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Peter Daniel DeYoung
Employees
7,120
Headquarters
Mumbai
Prihajajoči dogodki
11 NOV.
Earnings
Upcoming earnings report